Frédéric Lehmann

Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory Receptor

Hideyuki Ikeda, Bernard Lethé, Frédéric Lehmann et al. · Immunity · 1997 · 772 citations · Full text

Life Sciences, Immunology, Oncology +16

Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

Fernando Ulloa‐Montoya, Jamila Louahed, Benjamin Dizier et al. · Journal of Clinical Oncology · 2013 · 475 citations · Full text

Medicine, Immunology, Oncology +17

A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.

Pierre G. Coulie, Frédéric Lehmann, Bernard Lethé et al. · Proceedings of the National Academy of Sciences · 1995 · 421 citations · Full text

Life Sciences, Genetics, Immunology +17

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma

Susanne H.C. Baumeister, Joana Murad, Lillian Werner et al. · Cancer Immunology Research · 2018 · 325 citations · Full text

Pharmacy, Immunology, Oncology +17

Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study Results

Johan Vansteenkiste, M. Zieliński, A. Linder et al. · Journal of Clinical Oncology · 2013 · 314 citations · Full text

Medicine, Immunology, Oncology +16